Modality
Fusion Protein
MOA
TYK2i
Target
CD123
Pathway
mTOR
AML
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
~Feb 2022
→ ~May 2023
Phase 2
Aug 2023
→ Apr 2030
Phase 2Current
NCT07339261
2,885 pts·AML
2023-08→2030-04·Recruiting
NCT08202294
1,600 pts·AML
2025-06→2026-10·Terminated
4,485 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-277mo awayPh3 Readout· AML
2030-04-144.0y awayPh3 Readout· AML
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2026-10-27 · 7mo away
AML
Ph3 Readout
2030-04-14 · 4.0y away
AML
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07339261 | Phase 2/3 | AML | Recruiting | 2885 | Mayo |
| NCT08202294 | Phase 2/3 | AML | Terminated | 1600 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Olpainavolisib | Moderna | Phase 1 | Menin |